Cepheid gains grant for tuberculosis test:
This article was originally published in Clinica
Cepheid has been awarded a grant from the US National Institutes of Health to develop rapid diagnostic tests for Mycobacteria tuberculosis. The tests will be developed using Cepheid's GeneXpert platform, which is designed to provide a fully automated genetic assessment result. The platform can detect multiple DNA sequences in the same reaction, allowing for rapid, real-time analysis of antibiotic resistance, says the Sunnyvale, California firm.